ASX Announcements
Update - Notification of buy-back - COH
Daily Share Buy-Back Notice
Update - Notification of buy-back - COH
Daily Share Buy-Back Notice
Update - Notification of buy-back - COH
Daily Share Buy-Back Notice
Update - Notification of buy-back - COH
Daily Share Buy-Back Notice
Update - Notification of buy-back - COH
Daily Share Buy-Back Notice
February
Trump tariffs shake Australia; Investing tips for shifting markets; Rich Lister drops $19.5m on Manly home
Read everything that’s happened in the news so far today.
Cochlear says US cost-of-living pressures hit services revenue
Cochlear expects full-year earnings to come in at the lower end of guidance, despite rising sales of its implants.
October 2024
Cochlear-backed medtech Epiminder seeks $200m val in pre-IPO raise
The company expects its implants to be commercially available in the US market in 2027.
Unlikely winners of ATO’s R&D tax rules
The tax office’s first transparency report on R&D tax credits reveals the unlikely winners of the system.
August 2024
Cochlear shares slide after missing market expectations
Cochlear says sales of its hearing implants globally will drive profit higher by between 6 per cent and 11 per cent this year.
Jobless rate climbs; Telstra profits drop; KPMG partner pay slides
Read everything that’s happened in the news so far today.
May 2024
‘Business spends bugger all’: what landmark R&D review aims to fix
Technology industry experts warn a new government review into the R&D system must not cut tax incentives, and must kick-start anaemic business investment.
March 2024
Can a vaccine slow down the Cochlear train?
Cochlear is firing for investors, but you have to wonder whether everyone’s getting a bit carried away.
February 2024
Cochlear’s big first half delivers record earnings and dividend
The company reported its best interim sales and underlying net profit thanks to strong growth for its core hearing implants and services.
Why analysts love these eight medtech stocks
The sector that straddles healthcare and tech has professionals searching for companies that could be tomorrow’s big winners after Pro Medicus.
Cochlear lifts guidance despite Moderna vaccine threat
The hearing implant device maker’s shares rose more than 3 per cent after the company lifted its earnings forecasts.
January 2024
This fundie blasted Rio Tinto – then doubled down on his investment
WaveStone Capital’s Raaz Bhuyan talks about his latest trip to the Pilbara and how he was horrified by the miner’s initial response to the Juukan Gorge scandal.
December 2023
Schroders says Origin Energy assets ‘undervalued’
The head of Australian equities at the $1.3 trillion fund manager says returns in the energy sector will have to increase to attract more capital.
September 2023
Seven growth stocks for the next 10 years
To help navigate the volatile macro environment of high inflation and rising interest rates, we asked some of Australia’s best stock pickers for their longer-term standouts.
August 2023
Technology float CurveBeam AI graduates to ASX
Medical software group Curvebeam AI hits the ASX boards on Wednesday, having won over fund managers from its pre-IPO days.
Profit season hits and misses | Property’s big problems | Is US inflation fight over?
In this week’s episode, James and Anthony pick through the hits and misses of reporting season, take a deep dive into the property sector, and look ahead to the Jackson Hole conference.
Blue chip Cochlear lays down blue-chip result, gets more expensive
Globally relevant, strong sales growth and profit and net cash. What’s not to like at Cochlear? The question is whether you would pay nearly 50 times forecast profit for a piece of it.
Cochlear investors hear siren call of higher profits
The hearing device maker, which grew profits but saw a margin squeeze, is forecasting a boost this year.
June 2023
Why earnings season might be full of surprises (and shocks)
Consensus earnings estimates are looking stale, opening the door for August’s reporting season to deliver some real shocks.
Labor bows to pressure on multinational tax disclosure
Amended legislation introduced to parliament on Thursday has wound back the plan significantly.